PureTech Health
InactivePRTC (NGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
PureTech Health plc develops and commercializes biotechnology and pharmaceutical solutions in the United States. It is advancing LYT-100 (Phase 2) to treat idiopathic pulmonary fibrosis, and LYT-200, an IgG4 monoclonal antibody (Phase 1/2) targeting galectin-9 for solid tumors and blood cancers. It also develops SPT-300, an oral allopregnanolone for anxious depression, hydrogels for oral peptide delivery, and bacterial-consortia and stem-cell therapies, plus a voice-based health platform. Founded 2015, Boston.
Company score
- Sentiment
- 1.81
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 2.28
- Governance
- -1.15
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.43
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 1.12
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!